On Apr. 28, 2020, Secarna Pharmaceuticals announced the company has entered into a cooperation with the First Affiliated Hospital at Guangzhou Sun Yat-sen University for the development of a treatment or prophylactic for SARS-CoV-2 viral infections.

Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.